We are live on ! Find out more
FFM

Fairmount Funds Management Portfolio holdings

AUM $1.38B
1-Year Est. Return 407.79%
This Fund
S&P 500
This Quarter Est. Return
+32.98%
1 Year Est. Return
+407.79%
3 Year Est. Return
+2,937.62%
5 Year Est. Return
+5,415.3%
10 Year Est. Return
–
AUM
$569M
AUM Growth
+$132M
Cap. Flow
+$70.2M
Cap. Flow %
12.34%
Top 10 Hldgs %
65.09%
Holding
29
New
2
Increased
9
Reduced
4
Closed
2

Top Buys

Rank Stock Value
1
AXSM icon
Axsome Therapeutics
AXSM
+$47.7M
2
VRNA
Verona Pharma
VRNA
+$14.8M
3
TRVI icon
Trevi Therapeutics
TRVI
+$13.4M
4
PNT
POINT Biopharma Global Inc. Common Stock
PNT
+$8.49M
5
VRDN icon
Viridian Therapeutics
VRDN
+$7.65M

Top Sells

Rank Stock Value
1
GBT
Global Blood Therapeutics, Inc.
GBT
+$30.5M
2
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
+$13.4M
3
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$10.3M
4
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$8.81M
5
OLMA icon
Olema Pharmaceuticals
OLMA
+$6.1M

Sector Composition

Rank Sector Weight
1 Healthcare 95.29%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AXSM icon
1
Axsome Therapeutics
AXSM
$12.3B
$84.6M 14.88%
1,896,647
+954,076
+101% +$47.7M
COGT icon
2
Cogent Biosciences
COGT
$6.91B
$41.2M 7.24%
2,758,975
– –
NUVL
3
DELISTED
Nuvalent
NUVL
$40.4M 7.11%
2,079,863
+364,345
+21% +$6.1M
BCRX icon
4
BioCryst Pharmaceuticals
BCRX
$2.49B
$32M 5.63%
2,543,107
-800,000
-24% -$10.3M
BHVN
5
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$31M 5.44%
204,743
-59,463
-23% -$8.81M
NBIX icon
6
Neurocrine Biosciences
NBIX
$17.8B
$30.1M 5.28%
283,000
– –
INSM icon
7
Insmed
INSM
$22.9B
$28.8M 5.06%
1,336,368
+10,000
+0.8% +$240K
VRDN icon
8
Viridian Therapeutics
VRDN
$2.2B
$28.1M 4.94%
1,369,623
+425,531
+45% +$7.65M
VRNA
9
DELISTED
Verona Pharma
VRNA
$27.4M 4.81%
2,678,982
+1,752,380
+189% +$14.8M
AXSM icon
10
CALL
Axsome Therapeutics
AXSM
$12.3B
$26.8M 4.71%
+600,000
New +$30M
ARGX icon
11
argenx
ARGX
$56.1B
$26M 4.56%
73,526
– –
ENTA icon
12
Enanta Pharmaceuticals
ENTA
$375M
$24.3M 4.28%
469,264
– –
PNT
13
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$21.9M 3.85%
2,833,950
+1,000,000
+55% +$8.49M
ANNX icon
14
Annexon
ANNX
$875M
$20.8M 3.65%
3,358,563
+465,963
+16% +$2.52M
DBVT
15
DBV Technologies
DBVT
$813M
$12.5M 2.2%
706,496
+223,380
+46% +$5.18M
TYRA icon
16
Tyra Biosciences
TYRA
$1.89B
$12.5M 2.19%
1,416,998
– –
ACAD icon
17
Acadia Pharmaceuticals
ACAD
$4.4B
$12.3M 2.16%
751,804
– –
TERN
18
DELISTED
Terns Pharmaceuticals
TERN
$12.1M 2.12%
+2,050,000
New +$7.62M
ONC
19
BeOne Medicines Ltd
ONC
$33.9B
$11.6M 2.05%
86,400
-25,000
-22% -$4.29M
KROS icon
20
Keros Therapeutics
KROS
$205M
$10.3M 1.8%
272,498
– –
TRVI icon
21
Trevi Therapeutics
TRVI
$2.57B
$8.77M 1.54%
5,696,515
+4,072,126
+251% +$13.4M
ATXS
22
DELISTED
Astria Therapeutics
ATXS
$8.24M 1.45%
911,736
– –
AMRN
23
Amarin Corp
AMRN
$286M
$6.09M 1.07%
279,242
– –
IOVA icon
24
Iovance Biotherapeutics
IOVA
$2.2B
$3.73M 0.66%
389,588
– –
OLMA icon
25
Olema Pharmaceuticals
OLMA
$1.08B
$3.4M 0.6%
1,231,566
-1,437,734
-54% -$6.1M
1
2

Similar funds

NIP
Nicholas Investment Partners Rancho Santa Fe, California $1.39B AUM 97.11% 1-Year Est. Return
OCAM
Owl Creek Asset Management New York $1.38B AUM 59.67% 1-Year Est. Return
AU
Algebris (UK) London, United Kingdom $1.38B AUM 3.87% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
VC
Vestor Capital Chicago, Illinois $1.38B AUM 39.2% 1-Year Est. Return
AO
Advisor OS Chicago, Illinois $1.38B AUM 16.6% 1-Year Est. Return
1CP
1607 Capital Partners Richmond, Virginia $1.39B AUM 8.35% 1-Year Est. Return
OCM
Opti Capital Management New York $1.39B AUM 0% 1-Year Est. Return

Fairmount Funds Management's Q3 2022 Portfolio in Review

As of Q3 2022, Fairmount Funds Management held 29 positions worth $569M, up 30% from $437M the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Fairmount Funds Management deployed $70.2M of net new capital in Q3 2022, opening 2 new positions and adding to 9 existing holdings. Its largest new stake was Terns Pharmaceuticals: 2,050,000 shares worth $12.1M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 100% a quarter earlier.

On the sell side, the largest reduction was BioCryst Pharmaceuticals, an estimated $10.3M trimmed.

  • Fairmount Funds Management's largest Q3 2022 buy was Terns Pharmaceuticals: 2,050,000 shares worth $12.1M.
  • Fairmount Funds Management added most to Axsome Therapeutics in Q3 2022, an estimated $47.7M increase.
  • Fairmount Funds Management's biggest Q3 2022 reduction was BioCryst Pharmaceuticals, cutting an estimated $10.3M.
  • Fairmount Funds Management fully exited Global Blood Therapeutics, Inc. in Q3 2022, selling an estimated $30.5M.
  • Fairmount Funds Management's ten largest holdings make up 65% of its $569M portfolio in Q3 2022.
  • Fairmount Funds Management opened 2 new positions and closed 2 in Q3 2022.
  • Fairmount Funds Management's portfolio value rose 30% quarter-over-quarter to $569M.

Based on Fairmount Funds Management's 13F filing for Q3 2022, filed 9 Nov 2022.